Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Rocbrutinib contre Pirtobrutinib dans les LCC/SLL R/R prétraitées par cBTKi (Phase 3)

11 novembre 2026 mis à jour par: Newave Pharmaceutical Inc

Une étude de phase 3 ouverte, randomisée, multicentrique du rocbrutinib (LP-168) contre le pirtobrutinib chez des sujets atteints de leucémie lymphoïde chronique (LLC) / lymphome lymphocytique de bas grade (LLBG) en rechute ou réfractaire prétraités par un inhibiteur covalent de la BTK (cBTKi)

This is a Phase 3, randomized, open-label, multicenter study comparing rocbrutinib (LP-168) versus pirtobrutinib in adult participants with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received a covalent Bruton's tyrosine kinase inhibitor (cBTKi). Approximately 306 participants will be randomized 1:1 to receive rocbrutinib 200 mg orally once daily or pirtobrutinib 200 mg orally once daily, administered continuously in 28-day cycles until disease progression, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria are met. Randomization will be stratified by presence of del(17p)/TP53 mutation (yes/no), reason for discontinuation of prior cBTKi therapy (toxicity vs disease progression), prior exposure to a BCL2 inhibitor (yes/no), and region (United States/China/rest of world). The primary endpoint is progression-free survival (PFS) assessed by an independent review committee (IRC) using iwCLL 2018 criteria for CLL and Lugano 2014 criteria for SLL. Key secondary objectives include overall survival, overall response rate, time-to-event outcomes, and safety/tolerability; exploratory objectives include health-related quality of life and biomarker assessments.

Aperçu de l'étude

Description détaillée

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are indolent B-cell malignancies characterized by accumulation of mature but dysfunctional lymphocytes. Covalent Bruton's tyrosine kinase inhibitors (cBTKis) have substantially improved outcomes for patients with CLL/SLL; however, disease progression on cBTKi therapy or intolerance leading to treatment discontinuation remains an important clinical challenge. Patients who discontinue cBTKi therapy due to progression have limited therapeutic options and may experience poor outcomes. Therefore, effective and well-tolerated therapies are needed for participants with relapsed or refractory (R/R) CLL/SLL who have previously received a covalent BTK inhibitor.

Rocbrutinib (LP-168) is a selective next-generation inhibitor of BTK, that can irreversibly inhibit WT BTK, and reversibly inhibit C481 mutated BTK, with activity against known resistance mutations for non-covalent BTKi, under investigation for the treatment of CLL/SLL. Pirtobrutinib is an oral BTK inhibitor with regulatory approval for adults with R/R CLL/SLL who have previously received a covalent BTK inhibitor (cBTKi). This Phase 3 study is designed to compare the efficacy and safety of rocbrutinib versus pirtobrutinib in adult participants with cBTKi-pretreated R/R CLL/SLL.

This is a Phase 3, randomized, open-label, multicenter study conducted at approximately 100 sites globally. Approximately 306 participants will be randomized in a 1:1 ratio to receive rocbrutinib (LP-168) or pirtobrutinib. Eligible participants are adults with confirmed R/R CLL or SLL who require therapy and have received prior treatment with a cBTKi. Participants may have received additional prior systemic therapies, including prior exposure to a BCL2 inhibitor. Key exclusion criteria include central nervous system involvement by CLL/SLL and clinically significant cardiovascular conditions, including uncontrolled arrhythmias and clinically relevant QTc prolongation.

Participants randomized to the investigational arm will receive rocbrutinib 200 mg orally once daily. Participants randomized to the active comparator arm will receive pirtobrutinib 200 mg orally once daily. Study treatments will be administered continuously in 28-day cycles until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-defined discontinuation criteria. Crossover between treatment arms is not permitted.

Randomization will be stratified based on prognostic and treatment-history factors, including: (1) del(17p) and/or TP53 mutation status, (2) reason for discontinuation of prior cBTKi therapy, (3) prior exposure to a BCL2 inhibitor, and (4) geographic region.

The primary endpoint is progression-free survival (PFS). PFS will be assessed by an independent review committee (IRC) to provide objective evaluation of disease status. Response and progression for participants with CLL will be assessed according to iwCLL 2018 criteria, while participants with SLL will be assessed using Lugano 2014 criteria.

Key secondary efficacy endpoints include overall survival (OS), overall response rate (ORR), duration of response (DOR), time to next treatment (TTNT), and event-free survival (EFS). Additional secondary objectives include characterization of the safety and tolerability of rocbrutinib relative to pirtobrutinib. Safety will be assessed through evaluation of adverse events (AEs), serious adverse events (SAEs), adverse events of special interest, deaths, physical examinations, vital signs, electrocardiograms, and clinical laboratory assessments. AEs will be graded using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. In addition, population pharmacokinetics will be evaluated to characterize exposure-response relationships.

Exploratory objectives include evaluation of patient-reported outcomes and health-related quality of life, as well as biomarker assessments aimed at characterizing disease biology, mechanisms of response and resistance, and potential predictors of clinical benefit.

Type d'étude

Interventionnel

Inscription (Estimé)

306

Phase

  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

      • Le Mans, France, 72037
        • Recrutement
        • Centre Hospitalier Le Mans
    • Illinois
      • Skokie, Illinois, États-Unis, 60077
        • Recrutement
        • Orchard Healthcare Research
    • Maryland
      • Bethesda, Maryland, États-Unis, 20817
        • Recrutement
        • The Center for Cancer and Blood Disorders-Bethesda
    • Nevada
      • Las Vegas, Nevada, États-Unis, 89102
        • Recrutement
        • Optum Medical Group (Rhodes) P.C.
    • North Carolina
      • Durham, North Carolina, États-Unis, 27705
        • Recrutement
        • Duke Adult Blood and Marrow Clinic
    • Ohio
      • Columbus, Ohio, États-Unis, 43210
        • Pas encore de recrutement
        • OSU Comprehensive Cancer Center
    • Pennsylvania
      • Pittsburgh, Pennsylvania, États-Unis, 15213
        • Recrutement
        • UPMC Hillman Cancer Center
    • Washington
      • Spokane, Washington, États-Unis, 99208
        • Recrutement
        • Medical Oncology Associates - Spokane

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Age ≥18 years;
  • Histologically confirmed CLL/SLL iwCLL 2018;
  • Relapsed or refractory disease requiring treatment;
  • Previously treated with prior lines of therapy including a covalent BTK inhibitor;
  • Measurable disease;
  • ECOG 0-2;
  • Adequate marrow, hepatic, and renal function;
  • TP53 mutation status confirmed by NGS;
  • 17p deletion status confirmed by FISH;

Exclusion Criteria:

  • Prior ncBTKi or BTK degraders;
  • Richter's transformation;
  • Confirmed prolymphocytic leukemia;
  • Uncontrolled comorbidities or infections;
  • Known CNS involvement by CLL/SLL;
  • Prior malignancy requiring active treatment (except certain adequately treated cancers) per protocol;
  • Pregnancy or breastfeeding;
  • Concomitant medications or conditions prohibited by protocol (e.g., strong drug-drug interaction risk);

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Rocbrutinib

200mg daily

The new generation, highly potent, ultra-selective BTK inhibitor with covalent and non-covalent dual binding mechanism, targeting both WT BTK and mutant BTK

Comparateur actif: Pirtobrutinib

200mg daily

Pirtobrutinib is a non-covalent BTK inhibitor.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
PFS assessed by IRC
Délai: From randomization until disease progression or death from any cause, assessed up to approximately 4 years.

Progression-Free Survival assessed by independent review committee. PFS is defined as the time from the date of randomization to disease progression or death from any cause, whichever occurs first. Those who do not experience disease progression or death at the time of analysis are censored according to the last evaluation time point.

From randomization until disease progression or death from any cause, assessed up to approximately 4 years.

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
OS
Délai: From randomization until death from any cause, assessed up to approximately 4 years

Overall survival is defined as the time from the date of randomization to death from any cause. Those who did not die during the analysis were censored according to the last date the subject is known to be alive.

From randomization until death from any cause, assessed up to approximately 4 years
PFS assessed by INV
Délai: From randomization until disease progression or death from any cause, assessed up to approximately 4 years.

Progression free survival assessed by investigator

From randomization until disease progression or death from any cause, assessed up to approximately 4 years.
ORR
Délai: From randomization until disease progression, assessed up to approximately 4 years

Overall response rate

From randomization until disease progression, assessed up to approximately 4 years
DOR
Délai: From first documented response until disease progression or death, assessed up to approximately 4 years

Duration of response

From first documented response until disease progression or death, assessed up to approximately 4 years
TTNT
Délai: From randomization to start of next anti-CLL/SLL treatment, assessed up to approximately 4 years.

Time to next treatment

From randomization to start of next anti-CLL/SLL treatment, assessed up to approximately 4 years.
EFS
Délai: From randomization until an event occurs, assessed up to approximately 4 years.

Event free survival

From randomization until an event occurs, assessed up to approximately 4 years.
Safety and tolerability
Délai: From first dose through 30 days after the last dose of study treatment (up to approximately 4 years)

Safety and tolerability will be assessed by the incidence, severity, and relationship of adverse events (AEs) and serious adverse events (SAEs), including deaths; adverse events leading to dose modification or discontinuation; and changes in clinical laboratory parameters. Adverse events will be graded per NCI CTCAE v5.0, with specific monitoring for clinically significant cardiac arrhythmias and bleeding events.

From first dose through 30 days after the last dose of study treatment (up to approximately 4 years)

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Health related quality of Life
Délai: From baseline through end of treatment and follow-up, assessed up to approximately 4 years.

Health-related quality of life (HRQoL) will be assessed using validated patient-reported outcome (PRO) questionnaires to evaluate participants' functioning and symptoms over time. HRQoL endpoints will include change from baseline in overall health status and selected symptom and function domains. For the Global Health Status/QoL and functional scales, higher scores indicate better quality of life and functioning. For symptom scales/items, higher scores indicate greater symptom burden (worse symptoms).

From baseline through end of treatment and follow-up, assessed up to approximately 4 years.

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

23 avril 2026

Achèvement primaire (Estimé)

30 octobre 2029

Achèvement de l'étude (Estimé)

30 juillet 2030

Dates d'inscription aux études

Première soumission

13 janvier 2026

Première soumission répondant aux critères de contrôle qualité

13 janvier 2026

Première publication (Réel)

15 janvier 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

12 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

11 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

INDÉCIS

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner